{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:44:57Z","timestamp":1778629497564,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA-184153"],"award-info":[{"award-number":["R01-CA-184153"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01-CA-183848"],"award-info":[{"award-number":["U01-CA-183848"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.adro.2025.101832","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:37:35Z","timestamp":1752615455000},"page":"101832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective Phase II Trial of Definitive Chemoradiation and Concurrent Nivolumab in Locally Advanced p16+ Oropharynx Cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-8348","authenticated-orcid":false,"given":"Samuel Nicholas","family":"Regan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithika","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal A.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhava","family":"Aryal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin S.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Walline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choonik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Aldous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Swiecicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Casper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven B.","family":"Chinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.P.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaz L.","family":"Stucken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Shuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Heft-Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa H.","family":"Lyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chad Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis P.","family":"Worden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-9970","authenticated-orcid":false,"given":"Michelle L.","family":"Mierzwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101832_bib0001","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0002","unstructured":"Centers for Disease Control and Prevention. Cancers associated with human papillomavirus, United States\u20142015\u20132019. 2022. Accessed February 15, 2025. https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no31-hpv-assoc-cancers-UnitedStates-2015-2019.htm"},{"key":"10.1016\/j.adro.2025.101832_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101832_bib0004","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/JCO.21.01961","article-title":"Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: Long-term results of the ORATOR trial","volume":"40","author":"Nichols","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0005","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/oncolo\/oyab001","article-title":"Comparison of the seventh and eighth edition of American Joint Committee on Cancer (AJCC) Staging for selected and nonselected oropharyngeal squamous cell carcinomas","volume":"27","author":"Vijayvargiya","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.adro.2025.101832_bib0007","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/cncr.32025","article-title":"Validation of NRG oncology\/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials","volume":"125","author":"Fakhry","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101832_bib0008","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx\u2014ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2025.101832_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2025.101832_bib0011","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijrobp.2022.12.015","article-title":"Long-term update of NRG\/RTOG 0522: A randomized phase 3 trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer","volume":"116","author":"Caudell","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101832_bib0012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","article-title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): A randomised, controlled, open-label phase 2 trial","volume":"16","author":"Mes\u00eda","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0013","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2025.101832_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0016","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ijrobp.2022.09.003","article-title":"Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: Phase II results of NRG-HN004","volume":"114","author":"Mell","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101832_bib0017","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0018","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): A randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003747","article-title":"Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer","volume":"10","author":"Hecht","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.adro.2025.101832_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007141","article-title":"Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck","volume":"11","author":"Johnson","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.adro.2025.101832_bib0021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): A multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0022","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2022.10.008","article-title":"Safety of nivolumab added to chemoradiation therapy platforms for intermediate and high-risk locoregionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504","volume":"115","author":"Gillison","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.adro.2025.101832_bib0023","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hed.25336","article-title":"Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"41","author":"Hawkins","year":"2019","journal-title":"Head Neck"},{"issue":"suppl 1","key":"10.1016\/j.adro.2025.101832_bib0024","first-page":"E805","article-title":"Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer","volume":"38","author":"Vainshtein","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.adro.2025.101832_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.radonc.2015.06.006","article-title":"Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy","volume":"116","author":"Samuels","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpainsymman.2016.11.002","article-title":"Exploratory factor analysis of NRG Oncology\u2019s University of Washington Quality of Life Questionnaire-RTOG modification","volume":"53","author":"Pugh","year":"2017","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.adro.2025.101832_bib0029","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1245\/s10434-014-3656-z","article-title":"Minimal clinically important differences in quality of life scores of oral cavity and oropharynx cancer patients","volume":"21","author":"Binenbaum","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.adro.2025.101832_bib0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma","volume":"28","author":"Cao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2025.101832_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106436","article-title":"Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma","volume":"143","author":"Bhambhani","year":"2023","journal-title":"Oral Oncol"},{"issue":"8","key":"10.1016\/j.adro.2025.101832_bib0032","doi-asserted-by":"crossref","first-page":"e2120055","DOI":"10.1001\/jamanetworkopen.2021.20055","article-title":"Development and Assessment of a Model for Predicting Individualized Outcomes in Patients With Oropharyngeal Cancer","volume":"4","author":"Beesley","year":"2021","journal-title":"JAMA Netw Open [Internet]"},{"key":"10.1016\/j.adro.2025.101832_bib0033","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2025.101832_bib0034","doi-asserted-by":"crossref","first-page":"S1399","DOI":"10.1016\/j.annonc.2022.08.029","article-title":"LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0035","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.adro.2025.101832_bib0036","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","article-title":"A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC","volume":"3","author":"Darragh","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.adro.2025.101832_bib0037","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1158\/1078-0432.CCR-23-0334","article-title":"Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: The INRT-AIR Phase II clinical trial","volume":"29","author":"Sher","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2025.101832_bib0038","unstructured":"Astra Zeneca. Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, stage III non-small cell lung cancer. 2023. Accessed February 25, 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/update-on-pacific-2-phase-iii-trial-for-imfinzi.html"},{"key":"10.1016\/j.adro.2025.101832_bib0039","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0040","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus\u2013unrelated head and neck cancer: A multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2025.101832_bib0041","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.adro.2025.101832_bib0042","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0043","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: A single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.adro.2025.101832_bib0044","first-page":"A594","article-title":"568 Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)","volume":"10","author":"Gillison","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.adro.2025.101832_bib0045","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-22-1522","article-title":"Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer","volume":"28","author":"Mierzwa","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.adro.2025.101832_bib0046","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijrobp.2023.03.043","article-title":"Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of (18)F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis","volume":"117","author":"Allen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":";42 (8):","key":"10.1016\/j.adro.2025.101832_bib0047","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/hed.26085","article-title":"Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin","author":"Swiecicki","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.adro.2025.101832_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01118","article-title":"Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16- High Risk Head and Neck Cancer","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2025.101832_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110281","article-title":"A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)","volume":"196","author":"de Leeuw","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425001198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425001198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:54:13Z","timestamp":1777632853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109425001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2452109425001198"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101832","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Phase II Trial of Definitive Chemoradiation and Concurrent Nivolumab in Locally Advanced p16+ Oropharynx Cancer","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101832"}}